Alfacell Receives First-Ever Pioneer Award for Mesothelioma Research From Mesothelioma Applied Research Foundation
Tuesday, October 11th, 2005.
Alfacell Corporation today announced that the Company was presented with a “Pioneer Award” from the Mesothelioma Applied Research Foundation (MARF) at its Second International Symposium on Malignant Mesothelioma, held last week in Las Vegas. The Pioneer Award was introduced by MARF this year to honor companies that have made substantial contributions to the field of mesothelioma research.
“It is a great honor to receive one of the first MARF Pioneer Awards,” stated Kuslima Shogen, Chief Executive Officer of Alfacell, who accepted the award on behalf of the Company. “Even greater was the opportunity to meet many patients and others who have lost loved ones to mesothelioma. It was humbling to receive their praise, and inspiring to witness their grace and determination to conquer this terrible disease.”
Shogen concluded, “MARF has done exceptional work in drawing much-needed attention to malignant mesothelioma, an insidious cancer that affects thousands around the world. Through the annual symposium, MARF also provides a unique, interdisciplinary forum for discussion of the scientific and clinical advances in the treatment of this disease. We salute MARF for their efforts, and will continue to work with them on the mission to find a cure.”
In addition to Alfacell, other inaugural Pioneer Award recipients included Eli Lilly, Merck, Biogen Idec and Fujirebio Diagnostics.
For more information about MARF, a national nonprofit organization dedicated to eradicating mesothelioma as a life-threatening disease, visit www.marf.org.
About Alfacell Corporation
Alfacell Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer, using its proprietary ribonuclease (RNase) technology platform. ONCONASE(R) (ranpirnase), Alfacell’s lead investigational drug candidate, has been successfully administered to over 850 patients with a variety of solid tumors, and is currently being evaluated in a Phase IIIb trial for malignant mesothelioma (MM) and a Phase I / II trial in Non-Small Cell Lung Cancer (NSCLC). For more information, please visit www.alfacell.com.
« Mesothelioma News Main Page.
Most Recent in
Alfacell
- 10/10/08 - Paper in Cell Cycle Reports Alfacell’s ONCONASE® Targets siRNA
- 05/29/08 - Alfacell: Malignant mesothelioma treatment trial fails to meet primary endpoint
- 04/02/08 - Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
- 01/18/08 - Alfacell Announces ONCONASE(R) Purchase and Supply Agreement with Scientific Protein Laboratories
- 01/15/08 - Strativa Pharmaceuticals Acquires Commercialization Rights to Onconase(R) from Alfacell Corporation
Most Recent in
Drug Companies
- 04/13/09 - Prometheus and Rosetta Genomics Announce License and Collaboration Agreement
- 12/29/08 - Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) meso
- 10/10/08 - Paper in Cell Cycle Reports Alfacell’s ONCONASE® Targets siRNA
- 06/06/08 - The European Commission Grants Orphan Drug Designation for Molmed’s Vascular Targeting Agent Arenegyr in the Treatment of Mesothelioma
- 05/29/08 - Arenegyr: Key Preliminary Results of Phase II Trials in Mesothelioma and Colorectal Cancer Presented at ASCO
Most Recent in
Mesothelioma Applied Research Foundation (MARF)
- 06/22/09 - Mesothelioma Doctor, Advocate and Volunteers Recognized by the Mesothelioma Applied Research Foundation
- 05/20/09 - 2009 International Symposium on Malignant Mesothelioma: June 25-27
- 06/24/08 - Faces of Mesothelioma; Meso Foundation Press Conference with Families and Patients
- 05/17/08 - Congresswoman Lois Capps (D-CA) highlights need for asbestos ban
- 03/02/08 - MARF: Asbestos Dangers Persist
Most Recent in
Organizations
- 06/25/09 - CDC’s Morbidity and Mortality Weekly Report Analyzes Mesothelioma Death Rates
- 06/22/09 - Mesothelioma Doctor, Advocate and Volunteers Recognized by the Mesothelioma Applied Research Foundation
- 06/17/09 - EPA Announces Public Health Emergency in Libby, Montana; EPA to Move Aggressively on Cleanup and HHS to Assist Area Residents with Medical Care
- 06/05/09 - Asbestos Management Violations Settled at Bucks County School District
- 05/20/09 - 2009 International Symposium on Malignant Mesothelioma: June 25-27
You can follow any responses to this entry through the RSS 2.0 feed.
You can leave a response, or trackback from your own site.
